Article
Clinical Neurology
Johannes Lorscheider, Pascal Benkert, Carmen Lienert, Peter Haenni, Tobias Derfuss, Jens Kuhle, Ludwig Kappos, Oezguer Yaldizli
Summary: In a real-world setting, dimethyl fumarate and fingolimod demonstrate comparable effectiveness in reducing relapses and disability worsening in patients with RRMS. Findings from this study suggest that there is no significant difference in efficacy between the two treatment options, regardless of whether patients are treatment-naive or switching from another DMT.
JOURNAL OF NEUROLOGY
(2021)
Article
Immunology
Keita Takahashi, Hideyuki Takeuchi, Ryoko Fukai, Haruko Nakamura, Keisuke Morihara, Yuichi Higashiyama, Toshiyuki Takahashi, Hiroshi Doi, Fumiaki Tanaka
Summary: In these cases, patients developed relapses and seroconversion of anti-MOG antibodies after switching to DMF treatment, suggesting that DMF may exacerbate the humoral immune imbalance in MOGAD.
FRONTIERS IN IMMUNOLOGY
(2021)
Article
Clinical Neurology
Jannis Muller, Sabine Schadelin, Johannes Lorscheider, Pascal Benkert, Peter Hanni, Jurg Schmid, Jens Kuhle, Tobias Derfuss, Cristina Granziera, Ozgur Yaldizli
Summary: This study compared the effectiveness of dimethyl fumarate (DMF) and teriflunomide in a real-world setting and found that DMF treatment was associated with better clinical outcomes.
EUROPEAN JOURNAL OF NEUROLOGY
(2023)
Article
Clinical Neurology
Luca Prosperini, Shalom Haggiag, Serena Ruggieri, Carla Tortorella, Claudio Gasperini
Summary: Based on real-world studies, we found that dimethyl fumarate (DMF) is slightly more effective than teriflunomide (TRF) in reducing the short-term relapse risk of relapsing-remitting multiple sclerosis. However, there were no significant differences in reducing confirmed disability worsening and treatment discontinuation between the two drugs.
Article
Clinical Neurology
Tammy Jiang, Tjalf Ziemssen, Sibyl Wray, Changyu Shen, Karin Soderbarg, James B. Lewin, Ivan Bozin, Mark S. Freedman
Summary: This study compared the differences between Diroximel fumarate (DRF) and ponesimod (PON) as well as DRF and teriflunomide (TERI) in terms of clinical and radiological outcomes. The study found that there was no strong evidence of differences between DRF and PON in the treatment of relapsing multiple sclerosis, but DRF showed improved efficacy compared to TERI.
Article
Clinical Neurology
Thanh Phuong Pham Nguyen, Dina Jacobs, Dylan Thibault, Allison W. Willis
Summary: Oral disease-modifying therapies demonstrate comparable effectiveness for multiple sclerosis patients in the real world, even in older adults. Despite the increasing number of multiple sclerosis patients globally over the age of 55, rates of hospitalizations for multiple sclerosis remain low among individuals using these therapies.
MULTIPLE SCLEROSIS AND RELATED DISORDERS
(2021)
Article
Immunology
Xiang Chu, Jie Zhang, Yingying Li, Ke Yuan, Xue Wang, Xiang Gui, Yueyue Sun, Chaonan Geng, Wen Ju, Mengdi Xu, Zhenyu Li, Lingyu Zeng, Kailin Xu, Jianlin Qiao
Summary: This study aimed to evaluate the effect of Dimethyl fumarate (DMF) on platelet function. The results showed that DMF significantly inhibited platelet aggregation and granule release, reduced platelet spreading and clot retraction, and prolonged bleeding time in mice. Furthermore, DMF also reduced the generation of reactive oxygen species and inhibited NF-κB activation and phosphorylation of ERK1/2, p38 and AKT. Overall, DMF inhibits platelet function and thrombus formation.
INTERNATIONAL IMMUNOPHARMACOLOGY
(2023)
Article
Clinical Neurology
Jan Hillert, Jon A. Tsai, Mona Nouhi, Anna Glaser, Tim Spelman
Summary: This study found similarities in treatment persistence, clinical effectiveness, and quality of life outcomes between teriflunomide and dimethyl fumarate in a Swedish real-world setting.
MULTIPLE SCLEROSIS JOURNAL
(2022)
Article
Clinical Neurology
Ismail Solmaz, Pinar Acar Ozen, Safak Parlak, Asli Tuncer, Banu Anlar
Summary: This study on POMS suggests that ARR decreases under any treatment, more significantly under nDMTs. nDMTs can reduce the rate of patients with CE lesions on MRI, but have no significant effect on lesion load. There is an increasing trend in ARR after the first year of both iDMT and nDMT, indicating the need for re-evaluation of treatment.
EUROPEAN JOURNAL OF PAEDIATRIC NEUROLOGY
(2022)
Article
Clinical Neurology
Silvia Delgado, Jeffrey Hernandez, Leticia Tornes, Kottil Rammohan
Summary: In this study, the authors presented six patients with relapsing-remitting MS who experienced an unexpected increase in disease activity after transitioning from fingolimod to DMF. Despite being stable on fingolimod for at least 1 year, all patients experienced relapse with enhancing lesions after switching to DMF. Additional studies are needed to determine the most effective treatment strategy after discontinuing fingolimod.
Article
Biochemistry & Molecular Biology
Tristan Rupp, Solene Debasly, Laurie Genest, Guillaume Froget, Vincent Castagne
Summary: The study demonstrates the potential therapeutic opportunities of Fingolimod and DMF in the treatment of non-small cell lung cancer (NSCLC) at the preclinical stage, showing different effects on tumor growth through different cellular mechanisms.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Article
Clinical Neurology
Amber Salter, Samantha Lancia, Gary Cutter, Ruth Ann Marrie, Jason P. Mendoza, James B. Lewin, Robert J. Fox Mellen
Summary: In this study comparing patients with MS treated with DMF or FTY over 5 years, there was no significant difference in long-term disability worsening, as assessed by the PDDS, between the two groups.
THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS
(2021)
Article
Medicine, Research & Experimental
Sereen Sandouka, Prince Kumar Singh, Aseel Saadi, Rhoda Olowe Taiwo, Yara Sheeni, Taige Zhang, Larin Deeb, Michelle Guignet, Steve H. White, Tawfeeq Shekh-Ahmad
Summary: This study demonstrates that DMF has the potential to serve as a therapeutic target for preventing and treating epilepsy through the activation of Nrf2.
JOURNAL OF TRANSLATIONAL MEDICINE
(2023)
Article
Clinical Neurology
Eizo Tanaka, Mitsuru Watanabe, Shoko Fukumoto, Katsuhisa Masaki, Ryo Yamasaki, Takuya Matsushita, Noriko Isobe
Summary: This retrospective observational study found that smoking is associated with disease activity in RRMS patients under oral DMD treatment. Current smokers had higher relapse rates and proportions of any disease activity, as well as shorter time to relapse compared to non-smokers. Therefore, RRMS patients should be advised to quit smoking even after initiating DMDs.
MULTIPLE SCLEROSIS AND RELATED DISORDERS
(2023)
Article
Immunology
Gisela Bevilacqua Rolfsen Ferreira da Silva, Sofia Pereira das Neves, Susana Cristina Roque Oliveira, Fernanda Marques, Anselmo Gomes de Oliveira, Fabio de Lima Leite, Joao Jose Cerqueira
Summary: By incorporating DMF into solid lipid nanoparticles (SLNs), it was found that the progression of experimental autoimmune encephalomyelitis (EAE) in mice could be effectively reduced, with a decrease in adverse effects such as lymphopenia.
JOURNAL OF AUTOIMMUNITY
(2022)